Literature DB >> 30105509

Improving the Specificity of PSA Screening with Serum and Urine Markers.

James T Kearns1, Daniel W Lin2,3.   

Abstract

PURPOSE OF REVIEW: Prostate cancer remains a significant public health burden. In order to decrease the morbidity and mortality associated with prostate cancer, serum prostate-specific antigen (PSA) screening has been used since the 1990s. However, there is concern for overdiagnosis of prostate cancer with widespread PSA screening, which could lead to overtreatment and its attendant morbidities. RECENT
FINDINGS: In order to avoid unnecessary biopsy and downstream effects including treatment of insignificant prostate cancer, a number of tests have been proposed to improve upon PSA screening. Increasing the specificity of prostate cancer screening above that of PSA testing should reduce the incidence of unnecessary prostate biopsy. However, an increase in specificity is associated with a decrease in sensitivity, so these tests must be balanced with the concern for missing the diagnosis of potentially significant disease. In this context, we present a review of six common biomarkers proposed to improve the specificity of prostate cancer screening-free PSA, prostate health index, 4Kscore, PCA3, Select MDx, and ExoDx Prostate(Intelliscore).

Entities:  

Keywords:  Biomarkers; PSA screening; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30105509     DOI: 10.1007/s11934-018-0828-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  25 in total

1.  Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.

Authors:  Aaron A Laviana; Annette M Ilg; Darlene Veruttipong; Hung-Jui Tan; Michael A Burke; Douglas R Niedzwiecki; Patrick A Kupelian; Chris R King; Michael L Steinberg; Chandan R Kundavaram; Mitchell Kamrava; Alan L Kaplan; Andrew K Moriarity; William Hsu; Daniel J A Margolis; Jim C Hu; Christopher S Saigal
Journal:  Cancer       Date:  2015-11-02       Impact factor: 6.860

2.  PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Authors:  Ina L Deras; Sheila M J Aubin; Amy Blase; John R Day; Seongjoon Koo; Alan W Partin; William J Ellis; Leonard S Marks; Yves Fradet; Harry Rittenhouse; Jack Groskopf
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Authors:  Stacy Loeb; Sanghyuk S Shin; Dennis L Broyles; John T Wei; Martin Sanda; George Klee; Alan W Partin; Lori Sokoll; Daniel W Chan; Chris H Bangma; Ron H N van Schaik; Kevin M Slawin; Leonard S Marks; William J Catalona
Journal:  BJU Int       Date:  2016-11-22       Impact factor: 5.588

5.  Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Authors:  Andrew Vickers; Angel Cronin; Monique Roobol; Caroline Savage; Mari Peltola; Kim Pettersson; Peter T Scardino; Fritz Schröder; Hans Lilja
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

6.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

7.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors:  M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.

Authors:  A Gupta; M J Roobol; C J Savage; M Peltola; K Pettersson; P T Scardino; A J Vickers; F H Schröder; H Lilja
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

10.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  BMC Med       Date:  2008-07-08       Impact factor: 8.775

View more
  10 in total

1.  Assessment of men's risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer.

Authors:  Kevin Koo; Elias S Hyams
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

2.  Multiparametric MRI Versus SelectMDx Accuracy in the Diagnosis of Clinically Significant PCa in Men Enrolled in Active Surveillance.

Authors:  Pietro Pepe; Giuseppe Dibenedetto; Ludovica Pepe; Michele Pennisi
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers.

Authors:  Ana Rita Lima; Joana Pinto; Carina Carvalho-Maia; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

4.  Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction.

Authors:  David Bidarra; Vera Constâncio; Daniela Barros-Silva; João Ramalho-Carvalho; Catarina Moreira-Barbosa; Luís Antunes; Joaquina Maurício; Jorge Oliveira; Rui Henrique; Carmen Jerónimo
Journal:  Front Oncol       Date:  2019-09-11       Impact factor: 6.244

5.  Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.

Authors:  Yuqian Gao; Yi-Ting Wang; Yongmei Chen; Hui Wang; Denise Young; Tujin Shi; Yingjie Song; Athena A Schepmoes; Claire Kuo; Thomas L Fillmore; Wei-Jun Qian; Richard D Smith; Sudhir Srivastava; Jacob Kagan; Albert Dobi; Isabell A Sesterhenn; Inger L Rosner; Gyorgy Petrovics; Karin D Rodland; Shiv Srivastava; Jennifer Cullen; Tao Liu
Journal:  Cancers (Basel)       Date:  2020-05-17       Impact factor: 6.639

Review 6.  Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.

Authors:  Thomas Litman
Journal:  APMIS       Date:  2019-05       Impact factor: 3.205

7.  Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.

Authors:  Zhong-Han Zhou; Feng Liu; Wen-Jie Wang; Xue Liu; Li-Jiang Sun; Yao Zhu; Ding-Wei Ye; Gui-Ming Zhang
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

8.  Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.

Authors:  Ana Rita Lima; Joana Pinto; Ana Isabel Azevedo; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Paula Guedes de Pinho; Márcia Carvalho
Journal:  Br J Cancer       Date:  2019-10-07       Impact factor: 7.640

9.  Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.

Authors:  Vera Constâncio; Sandra P Nunes; Catarina Moreira-Barbosa; Rui Freitas; Jorge Oliveira; Inês Pousa; Júlio Oliveira; Marta Soares; Carlos Gonçalves Dias; Teresa Dias; Luís Antunes; Rui Henrique; Carmen Jerónimo
Journal:  Clin Epigenetics       Date:  2019-12-02       Impact factor: 6.551

Review 10.  Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.

Authors:  Ana Rita Lima; Joana Pinto; Filipa Amaro; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Metabolites       Date:  2021-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.